Wynetta Giles‐Davis

2.1k total citations · 1 hit paper
31 papers, 1.7k citations indexed

About

Wynetta Giles‐Davis is a scholar working on Genetics, Immunology and Epidemiology. According to data from OpenAlex, Wynetta Giles‐Davis has authored 31 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Genetics, 19 papers in Immunology and 9 papers in Epidemiology. Recurrent topics in Wynetta Giles‐Davis's work include Virus-based gene therapy research (20 papers), Immunotherapy and Immune Responses (18 papers) and CAR-T cell therapy research (6 papers). Wynetta Giles‐Davis is often cited by papers focused on Virus-based gene therapy research (20 papers), Immunotherapy and Immune Responses (18 papers) and CAR-T cell therapy research (6 papers). Wynetta Giles‐Davis collaborates with scholars based in United States, Brazil and Poland. Wynetta Giles‐Davis's co-authors include Hildegund C.J. Ertl, Zhiquan Xiang, Anthony P Wlazlo, James M. Wilson, Julie C. Fitzgerald, Marcio O. Lasaro, Kimberly McCoy, Dongming Zhou, Scott E. Hensley and Zhi Quan Xiang and has published in prestigious journals such as The Journal of Immunology, Cancer Cell and Journal of Virology.

In The Last Decade

Wynetta Giles‐Davis

29 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy

2017 481 citations Raj K. Kurupati, Xiang Zhou et al. profile →

Peers

Countries citing papers authored by Wynetta Giles‐Davis

Since Specialization

Citations

This map shows the geographic impact of Wynetta Giles‐Davis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wynetta Giles‐Davis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wynetta Giles‐Davis more than expected).

Fields of papers citing papers by Wynetta Giles‐Davis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wynetta Giles‐Davis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wynetta Giles‐Davis. The network helps show where Wynetta Giles‐Davis may publish in the future.

Co-authorship network of co-authors of Wynetta Giles‐Davis

This figure shows the co-authorship network connecting the top 25 collaborators of Wynetta Giles‐Davis. A scholar is included among the top collaborators of Wynetta Giles‐Davis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wynetta Giles‐Davis. Wynetta Giles‐Davis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Treatment with the PPARα agonist fenofibrate improves the efficacy of CD8+ T cell therapy for melanoma 2023 ·Molecular Therapy — Oncolytics ·Mohadeseh Hasanpourghadi, (unknown), (unknown), Raj K. Kurupati, (unknown), Wynetta Giles‐Davis, (unknown), Xiaowei Xu, Hildegund C.J. Ertl	8
2	Heterologous chimpanzee adenovirus vector immunizations for SARS-CoV-2 spike and nucleocapsid protect hamsters against COVID-19 2022 ·Microbes and Infection ·Mohadeseh Hasanpourghadi, (unknown), (unknown), (unknown), (unknown), (unknown), Wynetta Giles‐Davis, Zhiquan Xiang, Xiang Zhou, Qin Liu, Swagata Kar, Hildegund C.J. Ertl	9
3	Hexon-modified Recombinant E1-deleted Adenovirus Vectors as Dual Specificity Vaccine Carriers for Influenza Virus 2012 ·Molecular Therapy ·Dongming Zhou, (unknown), (unknown), Raj K. Kurupati, Steven Tuyishime, Yan Li, Wynetta Giles‐Davis, Xiangyang Zhou, Zhiquan Xiang, Qin Liu, Sarah J. Ratcliffe, Hildegund C.J. Ertl	19
4	Augmentation of Primary Influenza A Virus-Specific CD8+ T Cell Responses in Aged Mice through Blockade of an Immunoinhibitory Pathway 2010 ·The Journal of Immunology ·Lauren J. DiMenna, (unknown), Elizabeth M. Parzych, Larissa H. Haut, Katrin Töpfer, Sara Abdulla, Hong Yu, (unknown), Wynetta Giles‐Davis, Dongming Zhou, Marcio O. Lasaro, Hildegund C.J. Ertl	23
5	An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector 2010 ·Nature Protocols ·Dongming Zhou, Xiangyang Zhou, Ang Bian, Hua Li, Heng Chen, Juliana C. Small, Yan Li, Wynetta Giles‐Davis, Zhiquan Xiang, Hildegund C.J. Ertl	49
6	Robust genital gag‐specific CD8⁺ T‐cell responses in mice upon intramuscular immunization with simian adenoviral vectors expressing HIV‐1‐gag 2010 ·European Journal of Immunology ·Larissa H. Haut, (unknown), Nia Tatsis, Lauren J. DiMenna, Wynetta Giles‐Davis, Aguinaldo R. Pinto, Hildegund C.J. Ertl	8
7	Adenovirus Vector-Induced Immune Responses in Nonhuman Primates: Responses to Prime Boost Regimens 2009 ·The Journal of Immunology ·Nia Tatsis, Marcio O. Lasaro, Shih‐Wen Lin, Zhi Quan Xiang, Dongming Zhou, Lauren J. DiMenna, Hua Li, Ang Bian, Sara Abdulla, Yan Li, Wynetta Giles‐Davis, Jessica C. Engram, Sarah J. Ratcliffe, Guido Silvestri, Hildegund C.J. Ertl, Michael R. Betts	42
8	A Preclinical Animal Model to Assess the Effect of Pre-existing Immunity on AAV-mediated Gene Transfer 2009 ·Molecular Therapy ·Hua Li, Shih‐Wen Lin, Wynetta Giles‐Davis, Yan Li, Dongming Zhou, Zhi Quan Xiang, Katherine A. High, Hildegund C.J. Ertl	35
9	Pre-existing AAV Capsid-specific CD8+ T Cells are Unable to Eliminate AAV-transduced Hepatocytes 2007 ·Molecular Therapy ·Hua Li, Samuel L. Murphy, Wynetta Giles‐Davis, Shyrie Edmonson, Zhiquan Xiang, Yan Li, Marcio O. Lasaro, Katherine A. High, Hildegund C.J. Ertl	86
10	Dendritic Cell Maturation, but Not CD8+ T Cell Induction, Is Dependent on Type I IFN Signaling during Vaccination with Adenovirus Vectors 2005 ·The Journal of Immunology ·Scott E. Hensley, Wynetta Giles‐Davis, Kimberly McCoy, Wolfgang Weninger, Hildegund C.J. Ertl	60
11	DNA vaccines against the human papillomavirus type 16 E6 or E7 oncoproteins 2004 ·Cancer Gene Therapy ·Anthony P Wlazlo, Hongying Deng, Wynetta Giles‐Davis, Hildegund C.J. Ertl	26
12	A Simian Replication-Defective Adenoviral Recombinant Vaccine to HIV-1 Gag 2003 ·The Journal of Immunology ·Julie C. Fitzgerald, Guangping Gao, Arturo Reyes‐Sandoval, George N. Pavlakis, Zhi Quan Xiang, Anthony P Wlazlo, Wynetta Giles‐Davis, James M. Wilson, Hildegund C.J. Ertl	177
13	Induction of CD8+ T Cells to an HIV-1 Antigen through a Prime Boost Regimen with Heterologous E1-Deleted Adenoviral Vaccine Carriers 2003 ·The Journal of Immunology ·Aguinaldo R. Pinto, Julie C. Fitzgerald, Wynetta Giles‐Davis, Guang Ping Gao, James M. Wilson, Hildegund C.J. Ertl	97
14	Genetic Adjuvants 2003 ·Humana Press eBooks ·Hildegund C.J. Ertl, Susanna Pasquini, Zhenning He, Hongying Deng, Louise C. Showe, Wynetta Giles‐Davis, Yijie Wang, InSug O‐Sullivan, Hilary D. Marston, Magdalena Blaszczyk‐Thurin, Zhiquan Xiang	1
15	Vaccine-induced CD8+ T cells eliminate tumors by a two-staged attack 2003 ·Cancer Gene Therapy ·Dariusz Kowalczyk, Anthony P Wlazlo, Wynetta Giles‐Davis, Andreas R. Kammer, Sunil Mukhopadhyay, Hildegund C.J. Ertl	21
16	A modified DNA vaccine to p53 induces protective immunity to challenge with a chemically induced sarcoma cell line 2002 ·Cellular Immunology ·(unknown), Dariusz Kowalczyk, InSug O‐Sullivan, Magdalena Blaszczyk‐Thurin, Zhi Quan Xiang, Wynetta Giles‐Davis, Hildegund C.J. Ertl	15
17	A method that allows easy characterization of tumor-infiltrating lymphocytes 2001 ·Journal of Immunological Methods ·Dariusz Kowalczyk, Anthony P Wlazlo, Magdalena Blaszczyk‐Thurin, Zhiquan Xiang, Wynetta Giles‐Davis, Hildegund C.J. Ertl	23
18	Staining of antigen activated lymphocytes (SAAL): a highly specific method for flow cytometric quantitation of tumor-specific CD8+ T cells 2000 ·Journal of Immunological Methods ·Dariusz Kowalczyk, Anthony P Wlazlo, Wynetta Giles‐Davis, Hildegund C.J. Ertl	6
19	In situ stimulation of a T helper cell hybridoma with a cellulose-bound peptide antigen 2000 ·Journal of Immunological Methods ·László Ötvös, (unknown), (unknown), Wynetta Giles‐Davis, Mark E. Rogers, (unknown), Ralf Hoffmann, Hildegund C.J. Ertl	17
20	The effect of CpG sequences on the B cell response to a viral glycoprotein encoded by a plasmid vector 1999 ·Gene Therapy ·Susanna Pasquini, Hao Deng, (unknown), Wynetta Giles‐Davis, H. C. J. Ertl	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact